conoGenetix GmbH

Germany

unknown

Stage

About

conoGenetix GmbH develops peptide-based therapeutics aimed at treating autoimmune diseases such as multiple sclerosis, arthritis and rheumatism. Their approach targets and selectively inhibits the portion of the immune system responsible for the autoimmune response while preserving other immune functions.

Explore conoGenetix GmbH's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.